This April, the EmVenio and PCM Trials team traveled to Washington, D.C., for the 2025 World Vaccine Congress. In addition to attending informative panels, lectures and sessions on everything from research to commercial manufacturing of vaccines, our team hosted a variety of events to engage with those in attendance.
Thad Wolfram, EmVenio’s Chief Strategy Officer, took the stage at the speaker session “Community-Based Solutions: Expanding Access and Equity in a Global Influenza Vaccine Trial” to share how EmVenio is revolutionizing trial participation. In his presentation, Thad highlighted the company’s commitment to improving vaccine accessibility through innovative solutions such as mobile visits and Community Research Sites.
He also detailed EmVenio’s approach in an ongoing flu vaccine trial, where clinical research sites are being combined with mobile visit capabilities through its parent company, PCM Trials. This strategy ensures that participation is more accessible and inclusive, a priority reflected in the trial’s demographics—51.3% of participants come from historically underrepresented racial and ethnic backgrounds, more than double the industry average of 25%.
Thad underscored the impact of this inclusive approach, pointing to the trial’s remarkable retention rates. Out of 104 patients randomized and 594 total study visits conducted, the dropout rate remains below 1%, a stark contrast to the industry average of approximately 18%. By making equitable access, retention, and representation key pillars of their research efforts, EmVenio is setting a new benchmark for inclusive and impactful clinical trials.
In addition to the panel, we also parked one of our mobile Community Research Sites at our vendor booth. These sites are a key element of increasing access to clinical trials for underrepresented populations. We invited conference attendees to tour our Community Research Site to better understand how this innovative solution conducts clinical trials and learn how it can be beneficial to their next trial.
Our team also hosted a happy hour at our booth, inviting everyone in attendance to come chat with us, grab a drink and unwind during the busyness of the week. We were excited to talk to everyone who came by to learn about our work!
Also in attendance was Dr. Deon Miller, our principal investigator who runs our research site located at Prime Healthcare’s Southern Regional Medical Center outside of Atlanta. Fun fact – Dr. Miller’s research site was one of our first brick-and-mortar clinical research site, adding another element to our clinical trial methods. Between these sites, Community Research Sites and home visits, we’re able to not only provide access to care but engage patients in meaningful ways that keep them active and participating in studies.
Last but not least, EmVenio Research won this year’s Vaccine Industry Excellence Award for Best Clinical Trial Company! We are honored to be recognized with this accomplishment. This is a testament to the dedication of our whole team and the incredible work they do day in and day out to make access to care and clinical trials possible for all. This award inspires us to continue our mission in providing access and excellence in clinical trials.
Whether you had a chance to talk with our team at the conference or not, we would love to connect to talk about future projects. Please contact us today to learn how we can support your next clinical trial.